Today: 30 June 2026
Browse Category

TSXV:ELBM 13 October 2025

Electra Battery Materials (ELBM) Stock Skyrockets on $30M Cobalt Refinery Funding – EV Metal Boom Ignites

Electra Battery Materials (ELBM) Stock Skyrockets on $30M Cobalt Refinery Funding – EV Metal Boom Ignites

Electra Battery Materials describes itself as “a leader in advancing North America’s critical minerals supply chain” for electric vehicles Electrabmc. Its flagship project is a cobalt sulfate refinery in Temiskaming Shores, Ontario – slated to become the continent’s first battery-grade cobalt plant. Cobalt sulfate is a key input for lithium-ion battery cathodes. Electra’s multi-phase plan is to convert raw minerals into refined battery chemicals and eventually recycle used batteries into fresh materials Electrabmc Electrabmc. To diversify feedstock, Electra is testing domestic cobalt sources: in Q2 it launched metallurgical assays of material from the Iron Creek deposit in Idaho and legacy Ontario “Cobalt Camp” mine sites Electrabmc. The goal is to use ethically sourced North American cobalt instead of relying on foreign supply. Another growth area is battery recycling: Electra completed an engineering study for an adjacent black-mass recycling plant that would recover cobalt, lithium, nickel and other metals from spent batteries Electrabmc. The company has a joint venture to pursue the first Indigenous-led EV battery recycling plant in Canada Electrabmc.

Stock Market Today

  • Pfizer (PFE) edges up on China GLP-1 reimbursement; 7.1% dividend yield turns heads
    June 29, 2026, 6:55 PM EDT. Pfizer Inc. (NYSE: PFE) edged up 0.4% to $24.37, lagging the S&P 500's 1.18% move. Shares saw a small bump after China cleared Pfizer's GLP-1 ecnoglutide and Innovent Biologics' mazdutide for its national insurance list. Wider market access could help, though price pressures are likely. Pfizer sits near 8.4x estimated 2026 adjusted EPS, and its dividend yield stands at 7.1%, keeping income investors interested even as the stock has been flat. GLP-1 e-commerce growth in China is picking up but still makes up a small slice next to Pfizer's $139.7 billion market cap and $59.5-$62.5 billion sales forecast. Adding these drugs to the insurance list should expand patient access, but prices may trend lower like other hospital drugs. Pfizer now lines up against Novo Nordisk and Eli Lilly in the China GLP-1 space.
Go toTop